THERAPY DOSSIER · th-1963da6edba7

Human umbilical cord mesenchymal stromal cells overexpressing thioredoxin-1 via adenoviral vector (hucMSC-Trx-1)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24223778 ↗2013Reported benefit

Infusion of Trx-1-overexpressing hucMSC prolongs the survival of acutely irradiated NOD/SCID mice by decreasing excessive inflammatory injury.

MouseRadiationNOD/SCIDmalen = Redox capacity experiment: four groups of six male miceInjection (systemic infusion)0.2 ml normal saline containing hucMSC-Trx-1 or unmodified…

Model: Acute radiation injury from 4.5 Gy whole-body cobalt-60 gamma irradiation

hucMSC-Trx-1 gave superior antioxidant capacity, protected bone marrow haematopoietic stem cells (versus hucMSC p<0.05; versus saline p<0.01), promoted red blood cell and haemoglobin formation (p<0.05 versus both comparators), reduced inflammation and damage in bone marrow and lung (versus saline p…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…